A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
Work
Year: 2021
Type: article
Abstract: Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blin... more
Authors Marcia S. Brose, Y. Panaseykin, Bhavana Konda, Christelle De La Fouchardière, Brett Hughes +9 more
Institutions Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Medical Radiological Research Center, The Ohio State University, Centre Léon Bérard +10 more
Cites: 20
Cited by: 55
Related to: 10
FWCI: 8.825
Citation percentile (by year/subfield): 86.22
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid